Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (December 2017)
21 slides from Clearpoint Neuro's investor presentation, Dec 6, 2017
Slide 1: Investor Presentation
rr ~~ INTERVENTIONS Investor Presentation Joe Burnett, President & CEO December 6*, 2017 (© 2017 MRIINTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
2 Forward Looking Statements herein ing MRI ions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future as well as 's ions, beliefs, plans,
Slide 3: MRIC: The Premier Company for Precision MRI-Guided Therapy
MRIC: The Premier Company for Precision MRI-Guided Therapy MRI Interventions: Leader in Precision MRI-Guided Therapy Unique Platform that allows surgeons and researchers to deliver devices and therapies to the brain with pinpoint accuracy under live MRI Guidance Enables entire procedure to take plac
Slide 4: Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed Blind
Without ClearPoint®, Minimally Invasive Neuro Procedures Are Performed “Blind” Ce Procedure ClearPoint Neuro Procedure
Slide 5: The ClearPoint Neuro Navigation System Platform
The ClearPoint Neuro Navigation System Platform ClearPoint Procedure Overview: ClearPoint Video ClearPoint Video Entry and Trajectory Alignment and insertion VIDEO VIDEO (© 2017 MRIINTERVENTIONS, INC. | 5
Slide 6: Our MRI-Guided Therapy Platform is Currently Being Used to:
Our MRI-Guided Therapy Platform is Currently Being Used to: Implant Neuro Stimulation Products from: * Medtronic * St.Jude Medical * NeuroPac * Boston Scientific (Pending FDA Approval) Place Laser Ablation Probes from: + Medtronic-Visualase + Monteris Medical Deliver Drugs and Biologics from: je * V
Slide 7: Broad and Growing User Base of Leading Neurosurgeons
Broad and Growing User Base of Leading Neurosurgeons ClearPoint” Is Installed in 52 Top US Hospitals and Growing Univ of Minnesota Med Ctr 1am & Women's Strong Commercial Sales and Clinical Support Teams in Place (© 2017 MRI INTERVENTIONS, INC 7
Slide 8: Precision MRI-Guided Platform: ClearPoint Neuro Navigation System
Precision MRI-G led Platform: ClearPoint Neuro Navigation System ClearPoint Components: Capital Sale Reusable Hardware Components Integrated Software Uni of California San Francisco Medical Center Recurring Revenue Single-Use, Disposable Components Univ of Pittsburgh Medical Center © 2017 MAIINTERVE
Slide 9: Procedure CAGR, 2013-17: ~45% (est)
is CAGR, 2013-17: ~45% (est) Procedur 50 600 500 + aa, 2 146 ovedives 400 300 + Q2, 2017: 162 Procedures 200 + Q3, 2017: 300 || 161 Procedures 0 2013 2014 2015, 2016 2017 (© 2017 MRIINTERVENTIONS, INC. | 9
Slide 10: MRIC: 5-Year Growth Strategy
MRIC: 5-Year Growth Strategy wane we conmtoaion Q==) _ “geographies either direct or through partners. tee @) } dats Sent pi aang Pio @ CesPont Pam sae Tumor Biopsy ablation © ae cdeaten ad Deep Brain timation (085) for Parkinson's 2017 bse 2017 2022 Target Indications of > 150,000 procedures per ye
Slide 11: Existing Clinical Applications for Our ClearPoint System
EEE Existing Clinical Applications for Our ClearPoint System Complex and remote procedure where accuracy is paramount Electrode Placement and iat Biopsy VIDEO VIDEO Implant Neuro Stimulation Products from: * Medtronic + St. Jude Medical * NeuroPace + Boston Scientific (pending FDA Approval) Place La
Slide 12: Existing Research Applications for Our ClearPoint System
SS Existing Research Applications for Our ClearPoint System Drug Trials demand precise, efficient delivery to ensure the target is covered © VIDEO Deliver Drugs and Biologics from: opr * Voyager (Nasdaq:VYGR) PNoyages * Medicenna re) * Oxford Biomedica + International Stem Cell Corporation OxfordBio
Slide 13: Expansion into Direct Therapy Markets including Stroke
Expansion into Direct Therapy Markets including Stroke Leveraging Existing Capabilities and Install Base (s) Initial Stroke Product (ClearAway™) Targets Intracerebral Hemorrhage (ICH) * Collaboration with Mayo Clinic * Only major stroke subtype w/o clearly effective therapy — major unmet medical nee
Slide 14: Significant Pipeline of New Products and Indications
Significant Pipeline of New Products and Indications Sales Efficiency in U.S. and abroad will Expand with Broader Product Portfolio kiearablate™ - Pancreas (Gen 2) forug Tras in Progress Wovaer (Parkinson's isease) ford Biomesia (Parkinsons seas) hsogene(santippo A) foternational stom cel for Parkin
Slide 15: Expand Globally and Scale Current Business Model
Expand Globally and Scale Current Business Model Grow profit per procedure as we leverage sales expense and expand gross margin (6) Improve profit-per-procedure by leveraging existing sales infrastructure + Large sales expense comes from clinical specialist case coverage and travel + Reduce travel e
Slide 16: Addressable Markets for our MRI-Guided Therapy Platform
Addressable Markets for our MRI-Guided Therapy Platform Potential addressable markets in excess of $1B Prevalence | 1,500,000 | 2,200,000 | 0.000 90,000 50,000 4450.00 | 20,000 e | 32500 28,000 35,000 33,500 112,500 25,000 26,000, rage Salling Pea | _57500 $7,500 $7,500 $6,000 $5,000 $14,000, $8,000
Slide 17: Consistent Revenue Growth Since 2013
2 Consistent Revenue Growth Since 2013 $7,000,000 $6,000,000 $5,000,000 $4,000,000 $3,000,000 $2,000,000 $1,000,000 $ Total Revenue 2 | | 2013 201420152016. qi—Q3 2017 l@ Consumables m Capital / Service m Other + 75%¢ of revenue from single-use disposables isposable CAGR from 2013-2017: 30%+ (est) O
Slide 18: Cash Flow From Operations: 2015 - Q3, 2017
2 Cash Flow From Operations*: 2015 - Q3, 2017 $0 $500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Qi Q2 Q3 Q4 Ql Q2 Q3 QF Qi az a3 2015 2016 2017 (© 2017 MRIINTERVENTIONS, INC. | 18
Slide 19: Income Statement, Last Quarters
OO Income Statement, Last 5 Quarters Quarter Ended Revenues: Disposable product revenues $ 1272 $ 1363 $1,663 $1436 $1421 Reusable product revenues 309 224259 457208 Total product revenues 1581 1587 1,922 1,893 1,629 Service revenues 35 48 85 83 88 Total revenues 1,616 1,635 2,007 1,976 4717 Cost of
Slide 20: Experienced Medical Device Management Team
Experienced Medical Device Management Team Management Team Joseph Burnett cEO MVOLEAND usaany Peter Piferi coo “werwere Cordis, Wendelin Maners _VP Sales & Marketing SBE Re — Desameoica Hal Hurwitz CFO oe a Board of Directors son fame, | Jnr | rasan Toot Jack Spencer a er ae Baral Ows mae! (© 2017 M
Slide 21: Executive Summary
eee xecutive Summary Unique, Platform enabling mini y i for some of the most difficult and debilitating disorders Installed in 52 of 250+ leading Neurology centers in the U.S. * 75%+ of current revenue from single-use, high-margin disposables Procedure volume has grown 45%+ CAGR from 2013-2017 * Pip
MRI Interventions — Investor Presentation (December 2017) on 6ix